含有自由基组的多基2-素) 基脂类纳米囊作为传统PEG-脂类纳米囊的有希望的替代品
Stéphane Hoang1, Tetiana Dumych2, Solomiya Paryzhak2
1Univ Angers, Inserm, CNRS, MINT, SFR ICAT, F-49000 Angers, France.
ACS omega
|March 9, 2026
概括
基于聚2-zoline的脂质纳米囊 (POx LNCs) 为PEGylated纳米载体提供了一个有前途的替代品. 这些新型的POx LNCs表现出卓越的稳定性,低细胞毒性,并有可能用于先进的生物医学应用.
科学领域:
- 生物材料科学 生物材料科学
- 纳米技术 纳米技术
- 聚合物化学 聚合物化学
背景情况:
- 脂质纳米囊 (LNC) 是受青的纳米载体,因为稳定性和生物相容性.
- 在LNC中的聚乙烯糖醇 (PEG) 表面活性剂面临来自抗PEG抗体的挑战,影响临床使用.
- 聚二氧化 (POx) 具有与PEG相似的隐形特性,但免疫性较低,可调性更强.
研究的目的:
- 合成基于POx的表面活性剂用于LNC配方.
- 评估基于POx的LNCs的物理化学特性和稳定性.
- 评估POx LNCs作为无PEG替代品的体外和体内安全性和细胞兼容性.
主要方法:
- 通过无铜的亚酸环添加合成POx表面活性剂.
- 使用动态光散射 (DLS) 和纳米粒子追踪分析 (NTA) 进行LNC的表征.
- 在HeLa,HEK293和B16F10细胞系的体外细胞毒性测定和体内毒性研究.
主要成果:
- POx表面活性剂与疏水性链有效结合.
- POx LNCs 呈现出~63-74 nm 的水力动力直径和高度 (~10^14 nps mL^-1).
- POx LNCs在一个多月内表现出优异的体稳定性和与PEG LNCs相比的细胞相容性.
结论:
- 基于POx的表面活性剂可以成功地纳入LNC.
- POx LNCs是稳定的,细胞兼容的,并且在体内有毒性较低.
- POx LNCs代表了下一代纳米医学的可行,无PEG替代品.
相关概念视频
Bioavailability Enhancement: Drug Permeability Enhancement
283
After oral administration, poor permeability often limits the rate at which drugs are absorbed through the intestinal epithelium. Enhancing drug permeability is crucial for effective therapy, and several strategies have been developed to overcome this challenge.One effective strategy involves the use of lipid-based formulations. These formulations enhance dissolution and solubility, targeting physiological mechanisms to increase drug absorption. This includes stimulating bile salt secretion,...
283
Site-Targeted Drug Delivery Systems: Polymeric Carriers
71
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
71


